Modern Meadow announces partner Evonik to help bring lab-based leather to commercial scale

March 13, 2018
Accelerating Materials Innovation More...
Very important

Modern Meadow announced a partnership with Evonik to help scale its lab-grown leather to a commercially relevant capacity. This partnership will also involve improving the fermentation process itself, including optimizing Modern Meadow's collagen yield, helping to bring down some of the high production costs. While Modern Meadow previously emphasized its product development, including its artificial leather brand, its partnership with Evonik will be critical for commercial success. This is especially true given the historic struggles with scaling synthetic biology strains – Evonik will bring expertise in scaling fermentation processes to give Modern Meadow an improved chance of success.

For the original news article, click here .

Further Reading

Genomatica produces 1 ton of synbio-derived caprolactam in Slovenia

News Commentary | January 30, 2020

Two years after announcing that Aquafil would license its caprolactam technology, Genomatica has now produced a meaningful quantity of intermediate, to be polymerized into nylon 6 by Aquafil in Slovenia. However, the operation time of the fermentation process and Genomatica's production capacity for... Not part of subscription

Modern Meadow's technology pivot takes its bio-based leather closer to commercialization

Case Study | February 10, 2020

Modern Meadow had originally expressed its intent to make leather and meat using tissue engineering methods. The company's earlier patent applications outlined the use of edible microcarriers for cultured meat production. It later exclusively focused on bio‑based leather. For the production of bio‑... Not part of subscription

Genomatica announces big scale-up for bio-based nylon

News Commentary | November 20, 2020

Bio‑based nylon has been a holy grail for polymer developers, as it's widely used in products like apparel where consumers and brands value sustainable materials – but previous efforts, such as adipic acid routes from Verdezyne and Rennovia, have flopped based on poor economics. Now, Genomatica is ... Not part of subscription